Kip Piper's Health Care Blog
Medicare, Medicaid, Health Reform

Prescription drug spending rose by $135 billion between 2001 and 2010 to comprise approximately 12 percent of the nation’s overall healthcare outlay. While drug expenditure was one of the fastest growing components of U.S. healthcare spending prior to the early 2000s, generic drugs helped reduce the rate of annual...
The Patient-Centered Outcomes Research Institute (PCORI) has published its first set of proposed national priorities for research, Draft National Priorities for Research and Research Agenda Version 1. This 22-page publication highlights five focus areas for use in guiding comparative clinical effectiveness research and funding announcements. The Institute invites comments from...
Pharmaceutical manufacturers face an economic transformation as payors look more toward value-based – as opposed to transactional, unit-based – models for drug reimbursement.  This value-based revenue model presents enormous implications for the future of pharma and biotech, impacting everything from innovation, clinical trials, pricing, and marketing. The Health Research Institute at PwC surveyed...
As patents on brand-name drugs expire, and generic drug use increases, the United States, Europe, and Japan will account for a smaller share of worldwide spending on prescription drugs, a report from IMS Institute for Healthcare Informatics says. Yet rising incomes in countries such as Russia, China and India...
The 2012 Supreme Court got a lot of attention for its decision to uphold most of the Affordable Care Act (ACA) health reform law in NFIB v. Sebelius. But this year’s court docket will be no dud. There will be a number of interesting and important cases for pharma...
Generic drugs have operated under a different set of rules than brand-name drugs since 1984, when Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act. Brand-name drug manufacturers must submit extensive evidence from clinical trials to get approval from the Food and...
Patents form the basis of the  pharma and biotech industry, also called the life sciences industry. They give companies an incentive to make large investments in risky drug development and innovations, which have the potential to be ineffective or to fail Food and Drug Administration (FDA) approval. More than 6,000 U.S. businesses spent...
The prices of generic drugs vs. brand-name drugs has gathered a lot of attention lately. But buying in bulk and purchasing practices can have as much of an effect on prices as drug patents do.  That’s what the Government Accountability Office (GAO) found when it compared Rx prices paid in prescription...
The practice of medicine in the age of generic pharmaceuticals is built upon the premise that these chemically identical medications have the same therapeutic effect as the brand-name ones. But do they? Generic: The Unbranding of Modern Medicine by Jeremy A. Greene, MD, PhD, of John Hopkins University is...
The research and development pipeline for drugs and biologics is experiencing a tremendous surge in innovation, which will come to fruition within the next five years. This surge in prescription medicines will parallel a number of technology-enabled transformations in health care delivery that will dramatically increase access to health...

Stay Connected

4,688FansLike
6,936FollowersFollow
21,503FollowersFollow

Latest Articles